Corcept Therapeutics, Inc. (CORT)
116.23
+2.20
(+1.93%)
USD |
NASDAQ |
Oct 02, 16:00
116.23
0.00 (0.00%)
Pre-Market: 20:00
Corcept Therapeutics Net Income (Quarterly) : 42.14M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 42.14M |
| March 31, 2026 | -31.20M |
| December 31, 2025 | 23.90M |
| September 30, 2025 | 19.36M |
| June 30, 2025 | 34.61M |
| March 31, 2025 | 20.29M |
| December 31, 2024 | 30.39M |
| September 30, 2024 | 46.69M |
| June 30, 2024 | 35.12M |
| March 31, 2024 | 27.51M |
| December 31, 2023 | 31.14M |
| September 30, 2023 | 31.17M |
| June 30, 2023 | 27.36M |
| March 31, 2023 | 15.81M |
| December 31, 2022 | 16.53M |
| September 30, 2022 | 34.55M |
| June 30, 2022 | 27.41M |
| March 31, 2022 | 22.80M |
| December 31, 2021 | 32.05M |
| September 30, 2021 | 30.47M |
| June 30, 2021 | 26.52M |
| March 31, 2021 | 23.46M |
| December 31, 2020 | 25.99M |
| September 30, 2020 | 21.62M |
| June 30, 2020 | 28.33M |
| Date | Value |
|---|---|
| March 31, 2020 | 30.06M |
| December 31, 2019 | 29.38M |
| September 30, 2019 | 26.34M |
| June 30, 2019 | 20.19M |
| March 31, 2019 | 18.27M |
| December 31, 2018 | 22.01M |
| September 30, 2018 | 17.75M |
| June 30, 2018 | 18.20M |
| March 31, 2018 | 17.46M |
| December 31, 2017 | 98.33M |
| September 30, 2017 | 13.76M |
| June 30, 2017 | 12.65M |
| March 31, 2017 | 4.388M |
| December 31, 2016 | 4.597M |
| September 30, 2016 | 2.585M |
| June 30, 2016 | 0.977M |
| March 31, 2016 | -0.019M |
| December 31, 2015 | 0.959M |
| September 30, 2015 | -0.601M |
| June 30, 2015 | -1.936M |
| March 31, 2015 | -4.83M |
| December 31, 2014 | -3.895M |
| September 30, 2014 | -6.006M |
| June 30, 2014 | -7.552M |
| March 31, 2014 | -13.93M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Eli Lilly & Co. | 7.095B |
| Pfizer Inc. | -246.00M |
| Aclaris Therapeutics, Inc. | -21.50M |
| Bristol Myers Squibb Co. | 3.316B |
| Liquidia Corp. | 74.72M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 256.15M |
| Total Expenses (Quarterly) | 214.01M |
| EPS Diluted (Quarterly) | 0.356 |
| Enterprise Value | 12.24B |
| Gross Profit Margin (Quarterly) | 98.41% |
| Profit Margin (Quarterly) | 16.45% |
| Earnings Yield | 0.36% |
| Operating Earnings Yield | 0.05% |
| Normalized Earnings Yield | 0.3602 |